Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017 - Product Image

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017

  • ID: 4327703
  • Report
  • 246 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Bayer HealthCare AG
  • Bespak Europe Ltd
  • Boehringer Ingelheim GmbH
  • MORE
Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Bayer HealthCare AG
  • Bespak Europe Ltd
  • Boehringer Ingelheim GmbH
  • MORE
1. Table of Contents
2. Introduction
2.1 Dry Powder Inhaler Devices Overview
3. Products under Development
3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory
3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials
4. Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
5. Dry Powder Inhaler Devices Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.1.1 Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Adamis Pharmaceuticals Corp Company Overview
5.2.1 Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 Advent Pharmaceuticals Pty Ltd Company Overview
5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.4 Aespira Ltd. Company Overview
5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.5 AKELA Pharma Inc. (Inactive) Company Overview
5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.6 Bayer HealthCare AG (Inactive) Company Overview
5.6.1 Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.7 Bespak Europe Ltd Company Overview
5.7.1 Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 Boehringer Ingelheim GmbH Company Overview
5.8.1 Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.9 Circassia Pharmaceuticals Plc Company Overview
5.9.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
5.10 GlaxoSmithKline Plc Company Overview
5.10.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
5.11 MannKind Corp Company Overview
5.11.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
5.12 Monash University Company Overview
5.12.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview
5.13 Nanotherapeutics Inc Company Overview
5.13.1 Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.14 Nektar Therapeutics Company Overview
5.14.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
5.15 Novartis AG Company Overview
5.15.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.16 OPKO Health Inc Company Overview
5.16.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 Pharmaxis Ltd Company Overview
5.17.1 Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.18 Respira Therapeutics Inc Company Overview
5.18.1 Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.19 Sandoz International GmbH Company Overview
5.19.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.20 Sheffield Hallam University Company Overview
5.20.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
5.21 Shin Nippon Biomedical Laboratories Ltd Company Overview
5.21.1 Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.22 Sun Pharma Advanced Research Company Ltd Company Overview
5.22.1 Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.23 Teva Pharmaceutical Industries Ltd Company Overview
5.23.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.24 University of Kansas Company Overview
5.24.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
5.25 University of Texas Medical Branch at Galveston Company Overview
5.25.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
5.26 Vectura Group Plc Company Overview
5.26.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
5.27 Verona Pharma Plc Company Overview
5.27.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
5.28 Virginia Commonwealth University Company Overview
5.28.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
6. Dry Powder Inhaler Devices- Recent Developments
6.1 Jun 20, 2017: Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics
6.2 Jun 19, 2017: GSK confirms start date for Luke Miels
6.3 Jun 15, 2017: Consort Medical: Full year results
6.4 Jun 14, 2017: SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol - Fluticasone Dry Powder Inhaler (SPARC DPI)
6.5 May 23, 2017: Novartis' new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids
6.6 May 23, 2017: Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status
6.7 May 23, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
6.8 May 15, 2017: Sunovion to Present Data on Utibron Neohaler at the American Thoracic Society 2017 International Conference
6.9 May 11, 2017: Teva Reports First Quarter 2017 Financial Results
6.10 May 10, 2017: MannKind Reports 2017 First Quarter Financial Results
6.11 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results
6.12 May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017
6.13 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
6.14 May 05, 2017: Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
6.15 Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
6.16 Apr 26, 2017: Orion Group Interim Report January-March 2017
6.17 Apr 26, 2017: GSK delivers another quarter of continued progress
6.18 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
6.19 Apr 20, 2017: Teva Launches AirDuo RespiClick and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol
6.20 Apr 04, 2017: GSK responds to Cyclone Debbie
6.21 Apr 03, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
6.22 Mar 31, 2017: Verona Pharma Has Developed Its First-In-Class Product Candidate RPL554 As Dry Powder Inhaler
6.23 Mar 21, 2017: Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology
6.24 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016
6.25 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016
6.26 Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results
6.27 Mar 06, 2017: Vectura Group: Board Change
6.28 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development
6.29 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results
6.30 Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
6.31 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
6.32 Feb 22, 2017: Otsuka Pharmaceutical Certified as Excellent Health and Productivity Management Enterprise
6.33 Feb 16, 2017: FDA Expands Approval of SPIRIVA RESPIMAT (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
6.34 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products
6.35 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
6.36 Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results
6.37 Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017
6.38 Feb 08, 2017: Orion Group Financial Statement Release for 2016
6.39 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
6.40 Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman
6.41 Jan 30, 2017: Teva Announces FDA Approval of New AirDuo RespiClick Maintenance Inhalers for the Treatment of Asthma
6.42 Jan 30, 2017: Teva Announces FDA Approval of New ArmonAir RespiClick for the Treatment of Asthma
6.43 Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017
6.44 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
6.45 Jan 26, 2017: Achievement of sales milestone for COPD products
6.46 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
6.47 Jan 19, 2017: Abbas Hussain to leave GSK
6.48 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK
6.49 Jan 11, 2017: Vectura Group: Pre-close update
6.50 Jan 06, 2017: Teva Provides 2017 Financial Outlook
6.51 Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks
6.52 Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS
6.53 Dec 22, 2016: Teva Reaches Settlement with Government on FCPA
6.54 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges
6.55 Dec 21, 2016: Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler product family
6.56 Dec 19, 2016: Pulmatrix Receives Patents Important to its Inhaled Drug Delivery Technology
6.57 Dec 19, 2016: OPKO Health to be Added to the NASDAQ Biotechnology Index
6.58 Dec 19, 2016: GSK announces Board changes
6.59 Dec 14, 2016: Consort Medical: Directorate Change
6.60 Dec 08, 2016: Novartis' Ultibro Breezhaler Improved Lung Function And COPD Symptoms After Direct Switch From Previous Treatment
6.61 Dec 06, 2016: Consort Medical Reports Interim Results For The Six Months Ended 31 October 2016
6.62 Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson
6.63 Dec 01, 2016: Nanotherapeutics appoints president and CEO
6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
6.65 Nov 25, 2016: Consort Medical: CFO Appointment
6.66 Nov 21, 2016: GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
6.67 Nov 15, 2016: Teva Reports Third Quarter 2016 Results
6.68 Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results
6.69 Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer
6.70 Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results
6.71 Nov 03, 2016: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016
6.72 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016
6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
6.74 Oct 25, 2016: Orion Group Interim Report January-September 2016
6.75 Oct 17, 2016: New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk
6.76 Oct 12, 2016: New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray
6.77 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare
6.78 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
6.79 Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories
6.80 Sep 06, 2016: Tiotropium RESPIMAT Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
6.81 Sep 05, 2016: Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment
6.82 Aug 17, 2016: Consort Medical Announces Directorate Change
6.83 Aug 11, 2016: Asembia to Provide HUB and Patient Support Services for MannKind Corporation Related to Afrezza (insulin human) Inhalation Powder
6.84 Aug 11, 2016: Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs
6.85 Aug 08, 2016: OPKO Health Reports Improved Financial and Operating Results
6.86 Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results
6.87 Aug 04, 2016: Teva Reports Second Quarter 2016 Results
6.88 Aug 03, 2016: Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
6.89 Aug 03, 2016: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
6.90 Aug 03, 2016: Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer
6.91 Aug 01, 2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs
6.92 Jul 27, 2016: GSK announces significant new investment in UK manufacturing network
6.93 Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
6.94 Jul 21, 2016: Meda: Interim Report, January-June 2016
6.95 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
6.96 Jul 19, 2016: Orion Group Half-Yearly Report January-June 2016
6.97 Jul 15, 2016: PhRMA Welcomes Five New Member Companies
6.98 Jul 11, 2016: 3M Announces New Leadership Appointments
6.99 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down
6.100 Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award
6.101 Jul 06, 2016: Pulmatrix's iSPERSE Focus of Interview with News Medical
7. Appendix
7.1 Methodology

List of Tables
Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: CVT-301 Drug Delivery Device - Product Status
Table 10: CVT-301 Drug Delivery Device - Product Description
Table 11: CVT-427 Drug Delivery Device - Product Status
Table 12: CVT-427 Drug Delivery Device - Product Description
Table 13: Acorda Therapeutics Inc - Ongoing Clinical Trials Overview
Table 14: CVT-301 Drug Delivery Device - A 12 Month, Dose-level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients with Motor Response Fluctuations (OFF Phenomena)
Table 15: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 16: Taper DPI - Product Status
Table 17: Taper DPI - Product Description
Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 19: g60 Dry Powder Inhaler - Product Status
Table 20: g60 Dry Powder Inhaler - Product Description
Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 22: resQhaler - Product Status
Table 23: resQhaler - Product Description
Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Fentanyl TAIFUN Inhaler - Product Status
Table 26: Fentanyl TAIFUN Inhaler - Product Description
Table 27: Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status
Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description
Table 30: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 31: DEV610 DPI - Product Status
Table 32: DEV610 DPI - Product Description
Table 33: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Next Generation Respimat Inhaler - Product Status
Table 35: Next Generation Respimat Inhaler - Product Description
Table 36: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Tiotropium bromide DPI - Product Status
Table 38: Tiotropium bromide DPI - Product Description
Table 39: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 40: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Status
Table 41: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Description
Table 42: Gemini Multi-Dose Combination Inhaler - Product Status
Table 43: Gemini Multi-Dose Combination Inhaler - Product Description
Table 44: GlaxoSmithKline Plc - Ongoing Clinical Trials Overview
Table 45: ELLIPTA Dry Powder Inhaler - Closed Triple - A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI with the Fixed Dose Dual Combination of FF/VI, Administered Once-daily via a Dry Powder Inhaler in Subjects with Inadequately Controlled Asthma
Table 46: ELLIPTA Dry Powder Inhaler - Closed Triple - A Randomized, Open-label, Cross-over, Placebo-device Study Investigating Critical and Over All Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler (DPI) as Compared to HANDIHALER DPI Used in Combination with Either DISKUS DPI or TURBUHALER DPI, in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD)
Table 47: ELLIPTA Dry Powder Inhaler - Closed Triple - Description of the Ability to Learn How to Handle Inhaler Devices in Asthma - AUDIT
Table 48: MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 49: Dreamboat - Product Status
Table 50: Dreamboat - Product Description
Table 51: Monash University Pipeline Products & Ongoing Clinical Trials Overview
Table 52: Aerosol Delivery System - Product Status
Table 53: Aerosol Delivery System - Product Description
Table 54: Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 55: GelVac Intranasal Powder Vaccine Delivery System - Product Status
Table 56: GelVac Intranasal Powder Vaccine Delivery System - Product Description
Table 57: NanoGENT - Product Status
Table 58: NanoGENT - Product Description
Table 59: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
Table 60: Nektar Dry Powder Inhaler - Amikacin - Product Status
Table 61: Nektar Dry Powder Inhaler - Amikacin - Product Description
Table 62: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
Table 63: Seebri Neohaler - Product Status
Table 64: Seebri Neohaler - Product Description
Table 65: Ultibro Breezhaler - Product Status
Table 66: Ultibro Breezhaler - Product Description
Table 67: Novartis AG - Ongoing Clinical Trials Overview
Table 68: Ultibro Breezhaler - An Open-label, Low Interventional Clinical Study Investigating Error Rates (Critical and Overall) Prior to any Retraining in Correct use of the ELLIPTA Dry Powder Inhaler (DPI) Compared to other DPIs Including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a Monotherapy or in Combination, in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD)
Table 69: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD
Table 70: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 71: Inspiromatic - Product Status
Table 72: Inspiromatic - Product Description
Table 73: Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Orbital Dry Powder Inhaler - Product Status
Table 75: Orbital Dry Powder Inhaler - Product Description
Table 76: Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 77: RT234 AOS DPI - Product Status
Table 78: RT234 AOS DPI - Product Description
Table 79: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Solis Multi-Dose Dry Powder Inhaler - Product Status
Table 81: Solis Multi-Dose Dry Powder Inhaler - Product Description
Table 82: Unit-Dose Dry Powder Inhaler - Product Status
Table 83: Unit-Dose Dry Powder Inhaler - Product Description
Table 84: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
Table 85: Dry Powder Inhaler - Product Status
Table 86: Dry Powder Inhaler - Product Description
Table 87: Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 88: µco System - Product Status
Table 89: µco System - Product Description
Table 90: Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 91: SPARC DPI - Product Status
Table 92: SPARC DPI - Product Description
Table 93: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 94: ArmonAir RespiClick - Product Status
Table 95: ArmonAir RespiClick - Product Description
Table 96: Spiromax EU / mDPI US - Product Status
Table 97: Spiromax EU / mDPI US - Product Description
Table 98: Teva Pharmaceutical Industries Ltd - Ongoing Clinical Trials Overview
Table 99: Spiromax EU / mDPI US - Errors in the Use of Turbuhaler and Spiromax Devices Patients with Asthma
Table 100: ArmonAir RespiClick - 12-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma
Table 101: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
Table 102: Dry Powder Inhaler - Product Status
Table 103: Dry Powder Inhaler - Product Description
Table 104: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
Table 105: Dry Powder Drug Delivery System - Product Status
Table 106: Dry Powder Drug Delivery System - Product Description
Table 107: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 108: SKP-2075 - Product Status
Table 109: SKP-2075 - Product Description
Table 110: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 111: RPL554 - Dry Powder Inhaler - Product Status
Table 112: RPL554 - Dry Powder Inhaler - Product Description
Table 113: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
Table 114: Dry Powder Inhaler - Product Status
Table 115: Dry Powder Inhaler - Product Description
Table 116: Glossary

List of Figures
Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acorda Therapeutics Inc
  • Adamis Pharmaceuticals Corp
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Bayer HealthCare AG
  • Bespak Europe Ltd
  • Boehringer Ingelheim GmbH
  • Circassia Pharmaceuticals Plc
  • GlaxoSmithKline Pl
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll